{"type":"trials","record":{"id":18,"source_id":"clinicaltrials-gov","external_id":"NCT07092618","title":"Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation","brief_summary":"The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1 medications. The main questions it aims to answer are: * Whether the combination of metformin, with or without rapamycin or low-dose naltrexone, will be adequate to maintain the relative weight of individuals gradually discontinuing GLP-1 receptor agonist use. * Whether individuals discontinuing GLP-1 receptor agonist use who instead use a combination of metformin, with or without rapamycin or low-dose naltrexone, will experience less weight regain over the course of six months post-cessation than those who do not use any alternative medications. Researchers will compare the four groups: 1) control, 2) metformin, 3) metformin + rapamycin, and 4) metformin + low-dose naltrexone, to assess changes in the percentage of weight regain, metabolic indicators (e.g., HbA1c, lipid profile), and quality of life PROs, six months after cessation of GLP-1 therapy. Participants will: * Administer the assigned intervention following a dosing and administration protocol provided by the study and medical team. * Complete a medical intake for overall health status, medical history and demographic information, * Complete patient-reported outcomes/surveys and assessments * Complete blood work at baseline and every 16 weeks thereafter to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium). * Share data from health wearables with the research team throughout the study to improve the accuracy of evaluating activity, sleep, heart rate, and other related healthspan measures.","overall_status":"Recruiting","phases":["PHASE2","PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"AgelessRx","enrollment":150,"countries":["United States"],"start_date":"2024-12-17","completion_date":"2025-08-01","last_update_date":"2025-07-30","source_url":"https://clinicaltrials.gov/study/NCT07092618","editorial_summary":"A registered PHASE2, PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:44:58.543517+00:00","last_seen_at":"2026-09-16T06:17:38.682+00:00","metadata":{"acronym":null,"organization":"AgelessRx","source_has_results":false},"controlled_terms":["Longevity","GLP-1","Geroscience","Aging","Metformin","Rapamycin","Naltrexone","Vitamin C"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: metformin.","quality_checked_at":"2026-09-16T06:17:38.84842+00:00","duplicate_cluster_key":"id:nct07092618","duplicate_of_id":null,"clinical_trial_topics":[{"topic_slug":"metformin","is_published":true,"match_reasons":["Abstract contains controlled term: metformin.","Source terminology contains: metformin.","Abstract supplies longevity context: healthspan.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Metformin","slug":"metformin"}},{"topic_slug":"rapamycin","is_published":true,"match_reasons":["Abstract contains controlled term: rapamycin.","Source terminology contains: rapamycin.","Abstract supplies longevity context: healthspan.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Rapamycin","slug":"rapamycin"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/18","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}